Sintilimab
- Generic Name
- Sintilimab
- Drug Type
- Biotech
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Phase 1
Recruiting
- Conditions
- Advanced Intrahepatic Cholangiocarcinoma
- Interventions
- Biological: individualized anti-tumor new antigen iNeo-Vac-R01 injectionDrug: Gemcitabine + cisplatin (GP)
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 30
- Registration Number
- NCT06956716
- Locations
- 🇨🇳
the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer
Phase 4
- Conditions
- Localized Advanced Rectal Adenocarcinoma
- Interventions
- Drug: Intestinal microbiota capsulesRadiation: Standard Long Course RadiotherapyProcedure: Total mesorectal excision
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- First Affiliated Hospital of Ningbo University
- Target Recruit Count
- 20
- Registration Number
- NCT06931808
- Locations
- 🇨🇳
First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
Phase 2
Recruiting
- Conditions
- HCC
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Lei ZHAO
- Target Recruit Count
- 40
- Registration Number
- NCT06904014
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Nasopharyngeal Carcinoma (NPC)
- Interventions
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 664
- Registration Number
- NCT06900218
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 164
- Registration Number
- NCT06860490
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
Phase 1
Not yet recruiting
- Conditions
- Pancreatic Cancer Resectable
- Interventions
- Biological: individualized anti-tumor new antigen iNeo-Vac-R01 injection
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 60
- Registration Number
- NCT06888674
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang, China
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
Phase 1
Not yet recruiting
- Conditions
- Pancreatic Cancer MetastaticPancreatic Cancer Non-resectable
- Interventions
- Biological: individualized anti-tumor new antigen iNeo-Vac-R01 injectionDrug: mFOLFIRINOX Treatment Regimen
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 30
- Registration Number
- NCT06888648
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang, China
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 116
- Registration Number
- NCT06841159
- Locations
- 🇨🇳
Fudan University, Shanghai, China
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 160
- Registration Number
- NCT06837948
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
Phase 2
Not yet recruiting
- Conditions
- Colorectal Cancer Liver Metastasis
- Interventions
- Radiation: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT06788171
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath